our research

Benefits

Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange

February 2, 2023

Abbreviations

COVID‐19coronavirus disease‐2019PLExplasma exchangePOTSpostural orthostatic tachycardia syndromeSARS‐CoV‐2severe acute respiratory syndrome coronavirus‐2SFNsmall‐fiber neuropathy

Small‐fiber neuropathy (SFN) is a known complication of vaccinations, including the coronavirus disease‐2019 (COVID‐19) mRNA vaccines. 1 A 52‐year‐old man received the BNT162b2 mRNA COVID‐19 vaccine. After two doses, he had paresthesias as well as burning and stabbing pain in the arms, face, and eyes, accompanied by high‐pitched right ear tinnitus. He subsequently developed orthostatic intolerance and was unable to stand and walk without syncope. These symptoms progressed for 5 months and cardiac monitoring revealed significant postural tachycardia with heart rate varying from 50 beats per minute (bpm) supine to 180 bpm standing with episodes of supraventricular tachycardia. Neurological examination was normal except diminished sensation to temperature in the feet.

The following laboratory tests were normal or negative: comprehensive metabolic profile, complete blood count, vitamin B12 and B6 levels, thyroid‐stimulating hormone, homocysteine, methylmalonic acid, serum protein electrophoresis with immunofixation, paraneoplastic antibody profile, antinuclear antibody, double‐stranded DNA, Lyme antibody, C‐reactive protein, and erythrocyte sedimentation rate. Hemoglobin A1C was mildly elevated at 5.7%. Electromyography and nerve conduction studies were normal in the upper and lower extremities. Skin biopsy revealed decreased epidermal nerve fiber density of 2.2/mm2 (normal 13.8) at the distal leg and 7.5/mm2 at the thigh (normal 21.1). MRI of the brain and internal auditory canals was unremarkable. Expanded antibody testing (CellTrend Laboratories, Luckenwalde, Germany) revealed elevated titers of antibodies to multiple adrenergic receptors along with muscarinic cholinergic receptors and angiotensin‐converting enzyme 2 (ACE2) (Table 1).

See full text here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537871/

icon-document

Downloads Resources

Related Articles

Resources

Lipoprotein apheresis to treat elevated lipoprotein

icon-document

View the Research

Jan 25, 2024

Resources

Plasma Exchange Shows Promising Results in Alzheimer's Treatment: AMBAR Study

icon-document

View the Research

May 2, 2023

Resources

AMBAR Study Demonstrates the Feasibility of Two Plasma Exchange Modalities for Alzheimer's Treatment

icon-document

View the Research

May 2, 2023

Resources

Intermittent Heterochronic Plasma Exchange as a Modality for Delaying Cellular Senescence—A Hypothesis

icon-document

View the Research

May 2, 2023

Resources

Old plasma dilution reduces human biological age: a clinical study

icon-document

View the Research

May 2, 2023

Resources

Therapeutic plasma exchange (TPE) and blood products – Implications for longevity and disease

icon-document

View the Research

May 2, 2023

Resources

Novel Approach to Attenuate Age-Elevated Blood Factors through Repositioning Plasmapheresis

icon-document

View the Research

May 2, 2023

Resources

Randomized Controlled Trial of Plasma Exchange for Alzheimer's: AMBAR Study Findings

icon-document

View the Research

May 2, 2023

TPE Featured

COVID-19 Therapy: Therapeutic Plasmapheresis in Immunopathogenesis and Coagulopathy

icon-document

View the Research

May 2, 2023

Case Study

Plasmapheresis for brain fog in Long COVID

icon-document

View the Research

Feb 13, 2023